Comment on: Validation of biochemical scores for liver steatosis before and 1 year after sleeve gastrectomy

Over the past 10 years bariatric surgeons have embraced our role in not only producing sustained and long-term weight loss, but more importantly we have embraced our role in improving metabolic conditions, such as nonalcoholic fatty liver disease (NAFLD). With obesity increasing worldwide we have seen a concomitant increase in the number of patients who progress from NAFLD to nonalcoholic steatohepatitis (NASH) and ultimately cirrhosis [1]. Although we have increasing evidence of remission of NAFLD and NASH, the liver biopsy remains the gold standard for tracking regression and remission.

Source: Surgery for Obesity and Related Diseases - July 5, 2019 Category: Surgery Authors: Jason M. Johnson Tags: Editorial comment Source Type: research